Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection

Population Pharmacokinetic Analysis of Daclatasvir in Subjects with Chronic Hepatitis C Virus Infection

Background and Objective Daclatasvir is a potent, pangenotypic once-daily hepatitis C virus (HCV) NS5A inhibitor that is approved for the treatment of chronic HCV infection. The objective of this analysis was to characterize the pharmacokinetics of daclatasvir in subjects with chronic HCV infection....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Clinical pharmacokinetics 2017-10, Vol.56 (10), p.1173-1183
Hauptverfasser: Chan, Phyllis, Li, Hanbin, Zhu, Li, Bifano, Marc, Eley, Timothy, Osawa, Mayu, Ueno, Takayo, Hughes, Eric, Bertz, Richard, Garimella, Tushar, AbuTarif, Malaz
Format: Artikel
Sprache:eng
Schlagworte:
Antiviral drugs
Clinical trials
Cytochrome
Drug dosages
FDA approval
Genotype & phenotype
Hepatitis
Hepatitis C
Hepatology
Infections
Interferon
Internal Medicine
Medicine
Medicine & Public Health
Original Research Article
Patients
Pharmacokinetics
Pharmacology/Toxicology
Pharmacotherapy
Studies
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Background and Objective Daclatasvir is a potent, pangenotypic once-daily hepatitis C virus (HCV) NS5A inhibitor that is approved for the treatment of chronic HCV infection. The objective of this analysis was to characterize the pharmacokinetics of daclatasvir in subjects with chronic HCV infection. Methods A population pharmacokinetic (PPK) model was developed to evaluate effects of covariates on daclatasvir pharmacokinetics in subjects with chronic HCV infection ( n  = 2149 from 11 studies). All significant demographic, laboratory, prognostic and treatment covariates ( p  
ISSN:0312-5963
1179-1926
DOI:10.1007/s40262-016-0504-2